Mondher Mahjoubi: Sure. Thank you Daina. Same distribution to question one. The first one for Joyson. So you can update on the ERTC guidance for measurement of the anti-tumor activity in cutaneous T cell lymphoma. And then, Yannis, provide an answer on the BCMA IPH64 and CROSSODILE technology. Joyson, first you.
Joyson Karakunnel: Thanks, Mondher. So looking at the new guidance, it is a clarification of the prior guidance, and we want to go a little bit more into detail. So in the upcoming calls, we will describe in detail: number one, the different aspects of the guidance that are different, but number two is also our strategy going forward in how we’re going to approach the guidance, not only internally looking at the responses, but also in discussions with the regulators. Mondher?
Mondher Mahjoubi: Yannis?
Yannis Morel: Yes. Hello, Daina. Yes, the BCMA candidate is actually the molecular format is using what Sanofi is using, calling CROSSODILE, which is their commercial name for their, what you can find the literature as CODV for Cross-Over-Variable-Domain. So this is, I would say, the difference between ANKET and this is the special arrangement of the domains is a bit different. What we call ANKET at Innate are what co-creator re-molecular format plus our NKp46 proprietary binders. But we can actually plug in this NKp46 binder in our own proprietary format, but also on other, we can plug them in more generic format this including this CODV from Sanofi.
Mondher Mahjoubi: Daina, does — this address your question?
Daina Graybosch: Great. Thank you very much.
Mondher Mahjoubi: Okay. Thank you.
Operator: Your next question is from the line of Arthur He with HCW. Your line is open.
Arthur He: Hi, everyone. This is Arthur on for RK . Thanks for taking my question. I had one question regarding the lacutamab. So for the PCTL study, could you give us more color on the inclusion, exclusion criteria for the monotherapy you guys sponsored in the COMBO therapy? Is there any difference in term of that?
Mondher Mahjoubi: Sure. Nothing really — what to say, unique to this trial. But I’ll let, Joyson maybe remind you the criteria. As you know, there are two trials. There is a Phase 1b trial testing, lacutamab monotherapy in relapse refractory PTCL patient. And there is a second trial, which is in collaboration with the , which is testing the combination of chemotherapy, namely, gemcitabine, oxaliplatin in combination with lacutamab. And this is a randomized trial testing chemo versus chemo plus lacutamab. Joyson, can you provide a little bit more color on the monotherapy trial, which we are sponsoring.
Joyson Karakunnel: Yes, so the monotherapy trial specifically is KIR3DL2 positive patients, it is looking at relapse refractory line patients with no maximum lines of therapy. So, it is a general signal seeking trial and looking at the different subtypes also within it.
Arthur He: How about for the COMBO study? Is there any difference between the patient?
Joyson Karakunnel: Yes, the COMBO study is also, as Mondher had mentioned, the COMBO study has a comparator arm. So it does have a gemcitabine, oxaliplatin comparator, in addition to the combination arm. So in this, we are also recruiting KIR3DL2 positives, and then enrolling all relapse refractory with no maximum lines of therapy.
Arthur He: Thanks for that. My second question is, so first of all, congrats on the expanding collaboration with Sanofi. My question is for the — those two additional targets. Is there focus on the tri-specific, or it could target to the tetra-specific?
Mondher Mahjoubi: Yes, Yannis, we got this question previously when we announced the deal with Sanofi, so maybe you can clarify what is disclosed at least on the two options.
Yannis Morel: Yes, maybe it’s a good — thank you for the question to give me the opportunity to clarify this point. Actually, in our deal with Sanofi, we are licensing to them or giving them an option on the technology as it is today, meaning that we can and they can at some point decide to move under tri-specific format or tetra-specific format.
Arthur He: Okay, great. Thanks. Thanks for taking my question.
